Cedric Carter (Emeritus)

Contact Information
Life Sciences Centre
#4467 – 2350 Health Sciences Mall
Vancouver, BC V6T 1Z3
Tel: 1-604-822-7275
Email: cjcarter@interchange.ubc.ca

Current Positions

  • Associate Professor, Pathology & Laboratory Medicine, Medicine.

Research Interests

  • The development and demonstration of clinical efficacy of low molecular weight heparin fractions.
  • Investigation of a new antithrombin-III variant with discrepant functional to immuno ATIII levels.
  • Development of laboratory markers to detect hypercoagulable states.
  • Diagnostic application of platelet activation dependent antibodies.


  1. Smith, T.W., Carter, I.S.R., Smith, V.C., Carter, C.J. and MacGillivray, R.T.A. Identification of two novel mutations associated with combined protein C and protein S deficiency.  Dis. Therapeut. 2, 1-3 (2017).
  2. Arbaeen AF, Schubert P, Serrano K, Carter CJ, Culibrk B, Devine DV. Pathogen inactivation treatment of plasma and platelet concentrates and their predicted functionality in massive transfusion protocols. Transfusion. 2017 May;57(5):1208-1217.
  3. Shenoi,RA.*; Kalathottukaren, MT*; Travers, RJ; Lai, B.*; Creagh, AL.; Lange, D.; Chew, B.; Du, C.; Brooks, DE.; Carter, C.;Morrissey, JH.; Haynes CA.; Kizhakkedathu JN. (2014). Affinity-based design of a synthetic universal reversal agent for heparin anticoagulants. Science Translational Medicine. 6: 260ra150.
  4. Vanden Hoek AL, Talbot K, Carter IS, Vickars L, Carter CJ, Jackson SC, Macgillivray RT, Pryzdial EL. Coagulation factor X Arg386 specifically affects activation by the intrinsic pathway: a novel patient mutation. J Thromb Haemost. 2012 Dec;10(12):2613-5.
  5. Talbot K, Song J, Hewitt J, Serrano K, Ho M, Carter CJ, Macgillivray RT, Pryzdial EL. A novel compensating mechanism for homozygous coagulation factor V deficiency suggested by enhanced activated partial thromboplastin time after reconstitution with normal factor V. Br J Haematol. 2010 Oct;151(2):198-200.
  6. Carter ISR, Hewitt J, Pu CH, Wu JK, Carter CJ, MacGillivray RTA. Severe protein S deficiency resulting from two novel mutations in PROS1 presenting with a relatively mild clinical phenotype. J Thromb Haemost 2008; 6:1237-1239.
  7. Maurer-Spurej E, Kahr W, Carter CJ, Pittendreigh C, Cameron M, Cyr T. The value of proteomics for the diagnosis of a platelet-related bleeding disorder. Platelets. 2008 19(5):342-351.
  8. Zhang JG, Carter CJ, Culibrk B, Devine DV, Levin E, Scammell K, Weiss S, Gyongyossy-Issa MI. Buffycoat platelet variables and metabolism during storage in additive solutions or plasma. Transfusion. 2008 Feb 21; [Epub ahead of print].
  9. Zhang JG, Carter CJ, Devine DV, Scammell K, Weiss S, Gyongyossy-Issa MI. Comparison of a novel viscous platelet additive solution and plasma: preparation and in vitro storage parameters of buffy-coat-derived platelet concentrates. Vox Sang. 2008 Jan 4.


  • Senior Research Fellow, Ontario Heart Foundation, McMaster, 1985.
  • Research Fellow, Ontario Heart Foundation, McMaster, 1980.
  • FRCP(London), Internal Medicine, 1981
  • FRCP(C), Haematology, 1976
  • FRCP(C), Internal Medicine, 1976.
  • B.S., St. Thomas Hospital Medical School, 1969.
  • M.B., University of London, 1969.